Element Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Element Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-99,123	Closed	-$369K	–	905
2019 Q1	$369K	Buy	+99,123	New	+$335K	0.01%	524
2018 Q3	–	Sell	-104,080	Closed	-$244K	–	1113
2018 Q2	$244K	Sell	104,080 -108,766	-51%	-$304K	0.01%	635
2018 Q1	$626K	Buy	+212,846	New	+$581K	0.01%	273

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Element Capital Management's PDLI Position: Q2 2019 in Review

Element Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2019, closing a stake of 99,123 shares — an estimated $369K sold.

Element Capital Management first reported a position in PDLI in Q1 2018 and held it in 3 quarters. The position peaked at $626K in Q1 2018. 148 funds tracked by Wall St. Rank hold PDLI as of Q2 2019.

Element Capital Management reported no remaining PDL BioPharma, Inc. position as of Q2 2019 after selling out during the quarter.
Element Capital Management sold 99,123 PDL BioPharma, Inc. shares in Q2 2019, an estimated $369K.
Element Capital Management first reported a position in PDL BioPharma, Inc. in Q1 2018 and held it in 3 quarters.
Element Capital Management's PDL BioPharma, Inc. position peaked at $626K in Q1 2018.
148 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2019.

Based on Element Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.